You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Advanced Cannula Development for Coronary Sinus Access

    SBC: STRATEGIC PACING SYSTEMS LLC            Topic: NHLBI

    DESCRIPTION provided by applicant This Phase STTR will develop novel techniques for coronary sinus access The coronary sinus provides unique anatomic and physiologic proximity to all four cardiac chambers and the coronary circulation For example the coronary sinus is used for left ventricular lead insertion for biventricular pacing or cardiac resynchronization Mor than such implan ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Aerosol Sampling and Microfluidic Analysis of Reactive Oxygen Species

    SBC: ILLIONIX, LLC            Topic: 113

    DESCRIPTION provided by applicant Cardiovascular diseases and Asthma affects between and million people in the United States including million children during the past years its incidence worldwide has doubled Asthma is responsible for million person days of restricted activity and deaths per year amounting to $ billion in direct heath related costs there is uncertainty about the specific factors ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: 300

    DESCRIPTION provided by applicant Problem Lower gastrointestinal bleeding is a significant medical problem in the United States accounting for more than hospital admissions and tens of billions of dollars of healthcare spending annually It is common for bleeding from a single site to stop and restart multiple times The three modalities now used to diagnose and locate gastrointestina ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. A Sparse-readout Quantitative PET scanner for breast cancer therapy optimization

    SBC: PET/X LLC            Topic: 102

    The goal of this project is to develop a quantitative molecular breast imaging PET QMBI PET scanner to improve the way in which breast cancer therapies are matched to individual patients by providing evaluation of therapy efficacy during the window of opportunity between diagnosis and surgical resection More than women in the US with invasive disease start therapy for breast cancer each ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Clonotyping Technology for Prediction of Antibiotic Resistance

    SBC: ID GENOMICS SPC            Topic: NIAID

    DESCRIPTIONprovided by applicantThe primary goal of this proposal is to develop and finalize configuration of a rapid molecular diagnostics test to predict antibiotic resistance of th major human uropathogensEscherichia coliKlebsiella pneumoniaeEnterobacter spp and Pmirabilisby determining the sub species clonal identityclonotypeof the infecting bacteria directly from urine samplesCurrentlythe emp ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Developing a novel adjuvant system for therapeutic vaccines against lung cancer

    SBC: FasCure Therapeutics LLC            Topic: 102

    DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Development of An Integrated High Throughput Imaging and Image Analysis Platform for Muscle

    SBC: CytoInformatics LLC            Topic: NIA

    DESCRIPTION provided by applicant There is growing awareness that weakness of muscle is a significant biomedical health issue associated with many different chronic diseases and aging There are a variety of different diseases that affect muscle including muscular dystrophy fibromyalgia cerebral palsy amyotrophic lateral sclerosis and myasthenia gravis each of which carries its own uniqu ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Innovative Mitigation of Radiation Effects in Advanced Technology Nodes

    SBC: RELIABLE MICROSYSTEMS LLC            Topic: DTRA16A003

    Establish a radiation-aware analysis capability in a commercial EDA design flow that will enable first-pass success in radiation-hardened by design (RHBD) for DoD ASICs in much the same way that existing EDA design suites ensure first pass functionality and performance success of complex ASICs destined for commercial applications. Layout-aware, calibrated single-event radiation models that captur ...

    STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency
  9. Microfluidic Platform for Stem Cell Applications

    SBC: Nortis, Inc.            Topic: NCATS

    DESCRIPTION provided by applicant The emerging field of stem cell therapy has the potential to transform medicine forever However a major bottleneck for bringing stem cell therapies to the patient is the lack of adequate in vitro assays for the study of stem cell quality Critical test criteria are efficacy pluripotency prior to the differentiation process and safety lack of tumorigenicity ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Optimization of a computationally designed antiviral for influenza

    SBC: Virvio Inc            Topic: NIAID

    DESCRIPTION provided by applicant Influenza is a leading cause of death and morbidity in the US resulting in up to deaths hospitalizations and andgt $ billion in expenses per year Current antivirals incur high resistance rates and have low efficacy so there is a crucial need to develop better approaches to protect from seasonal influenza and future pandemics We aim to ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government